Acorda Therapeutics

Acorda Therapeutics Inc.
Public
Traded as NASDAQ: ACOR
S&P 600 Component
FWB: CDG
Industry Health care
Biotechnology
Founded 1995 (1995)[1]
Founder Ron Cohen
Headquarters Ardsley, New York, United States
Key people
 Ron Cohen (CEO)
Andrew R. Blight
Products Zanaflex
Ampyra
Qutenza
Revenue Increase US$588.22 Million (FY 2017)[2]
Increase US$35.1 Million (FY 2011)[2]
Increase US$30.6 Million (FY 2011)[2]
Total assets Increase US$379.5 Million (FY 2011)[2]
Total equity Increase US$205.2 Million (FY 2011)[2]
Number of employees
 328 (February, 2012) [2]
Website Acorda.com

Acorda Therapeutics Inc. is an American biotechnology company based in Ardsley, New York. The company develops drugs to improve therapies that improve neurological function in people with multiple sclerosis, spinal cord injury and other disorders of the central nervous system.[3] Acorda manufactures and markets the drugs Zanaflex, Ampyra and Qutenza in the United States.

History

In September 2014, the company acquired Civitas Therapeutics for $525 million - gaining the Phase III Parkinson’s drug, CVT-301.[4]

In January 2016, the company acquired Finnish pharmaceutical company, Biotie Therapies, for $363 million. This gave the company control over Biotes sclerosing cholangitis drug, BTT1023.[5]

In November 2016, Acorda Therapeutics announced it was discontinuing development of dalfampridine, a drug intended for post-stroke walking difficulties, after a clinical trial failure. The discontinuation of the drug caused Acorda's shares to drop as much as 13.2%. Acorda shares have dropped 50.2% since January 2016.[6]

Corporate governance

As of June 28, 2018, the members of the board of directors of Acorda Therapeutics were: Ron Cohen, Barry Greene, Peder K. Jensen, John P. Kelley, Sandra Panem, Lorin J. Randall, Steven M. Rauscher, and Ian F. Smith.[7]

Products

Products on the market

Development pipeline

References

  1. ↑ Acorda FAQ
  2. 1 2 3 4 5 6 "Acorda Therapeutics 2011 Annual Report - Form 10-K - February 28, 2012" (PDF). secdatabase.com. Retrieved May 16, 2012.
  3. ↑ Acorda 2008 10-K Annual report
  4. ↑ "Acorda Buys Civitas and Its Phase III PD Candidate for $525M - GEN News Highlights - GEN".
  5. ↑ "Accorda Acquires Biotie Therapies for $363 Million - GEN News Highlights - GEN".
  6. ↑ Court, Emma (November 21, 2016). "Acorda Therapeutics plummets as much as 13% on failed trial, discontinued drug development". Market Watch. Retrieved 16 December 2016.
  7. ↑ "Leadership ← Acorda".
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.